Trials / Withdrawn
WithdrawnNCT07375212
VAPorized Administration of Bumetanide for Outpatient Relief in Heart Failure
Acute Hemodynamic and Blood Volume Effects of Single-Dose Intranasal Bumetanide in Patients Implanted With the CardioMEMS™ and Cordella™ HF Systems: a 24-Hour Prospective Pilot Study
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Prisma Health-Upstate · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial is seeking to determine whether a single 4mg intranasal dose of bumetanide acutely reduces pulmonary artery pressure and blood volume in the outpatient setting for patients with heart failure and an implanted device for remote patient monitoring (i.e. Cordella or CardioMEMS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bumetanide, intranasal 4mg | Intranasal route of administration for 4mg of bumetanide |
Timeline
- Start date
- 2026-01-21
- Primary completion
- 2026-01-21
- Completion
- 2026-01-21
- First posted
- 2026-01-29
- Last updated
- 2026-01-29
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07375212. Inclusion in this directory is not an endorsement.